



The 4th World Congress on **CONTROVERSIES TO CONSENSUS IN DIABETES, OBESITY AND HYPERTENSION**



BARCELONA, SPAIN • NOVEMBER 8-11, 2012

CO-CHAIRPERSONS

S. Del Prato, *Italy* | I. Raz, *Israel*

PROGRAM DIRECTORS

S. Del Prato, *Italy* | P. Home, *UK* | I. Raz, *Israel*



www.codhy.com • codhy@codhy.com

ORGANIZING COMMITTEE

- | | | |
|---------------------------|----------------------------------|-----------------------------|
| W. Cefalu, USA | E. Grossman, Israel | P.M. Nilsson, Sweden |
| J. Chan, Hong Kong | V. Hainer, Czech Republic | S. Sadikot, India |
| J. Davidson, USA | P. Home, UK | E. Standl, Germany |
| R.A. DeFronzo, USA | M. Laakso, Finland | L. Van Gaal, Belgium |
| | L.A. Leiter, Canada | |

SCIENTIFIC COMMITTEE

- | | | |
|---------------------------------------|---------------------------------|---------------------------------|
| A. Avogaro, Italy | L. Heinemann, Germany | P. Pozzilli, Italy |
| R.G. Bretzel, Germany | S. Heller, UK | E. Ravussin, USA |
| A. Ceriello, Spain | B. Hirshberg, USA | F. Rubino, USA |
| S. Cernea, Romania | P. Iozzo, Italy | L.M. Ruilope, Spain |
| J.H. de Vries, The Netherlands | L. Ji, China | G. Schernthaner, Austria |
| D. de Zeeuw, The Netherlands | N.M. Lalic, Serbia | I. Shai, Israel |
| M. Donath, Switzerland | H. Lebovitz, USA | J. Škrha, Czech Republic |
| M. Federici, Italy | R. Lichiardopol, Romania | A. Solini, Italy |
| B. Frier, Scotland | G. Mancia, Italy | I. Tkac, Slovakia |
| B. Gallwitz, Germany | M.A. Nauck, Germany | H. Toplak, Austria |
| A.J. Garber, USA | A. Nicolucci, Italy | D. Tschöpe, Germany |
| Y. Handelsman, USA | P. Nilsson, Sweden | C. Tsigos, Greece |
| M. Hanefeld, Germany | G. Ning, China | J. Tuomilehto, Finland |
| T.A.M. Heagerty, UK | G. Perseghin, Italy | J. Wainstein, Israel |

PRELIMINARY FACULTY LIST

- | | | | |
|-------------------------------------|----------------------------------|-----------------------------|-----------------------------------|
| A. Ametov, Russia | B. Gallwitz, Germany | A. Lejniaks, Latvia | A. Scheen, Belgium |
| C. Bailey, UK | A. Garber, USA | D. Leroith, USA | G. Schernthaner, Austria |
| R. Bitzur, Israel | F. Giorgino, Italy | G. Lieberman, Israel | P. Schwarz, Denmark |
| R. Bonadonna, Italy | G. Grassi, Italy | V. Lyssenko, Sweden | J. Seufert, Germany |
| F. Bonnici, South Africa | E. Grossman, Israel | G. Mancia, Italy | M. Shestakova, Russia |
| E. Bonora, Italy | V. Hainer, Czech Republic | E. Mannucci, Italy | L. Sjostrom, Sweden |
| R.G. Bretzel, Germany | H. Haller, Denmark | G. Marchesini, Italy | J. Skrha, Czech Republic |
| C. Burrant, USA | M. Hanefeld, Germany | N. Marx, Germany | A. Solini, Italy |
| W. Cefalu, USA | S. Heller, UK | J. Meier, Germany | E. Standl, Germany |
| A. Ceriello, Spain | B. Hirshberg, Israel | D. Micic, Serbia | N. Stern, Israel |
| O. Cohen, Israel | J.C. Holm, Denmark | O. Mosenzon, Israel | C.J. Tack, The Netherlands |
| T. Cukierman-Yaffee, Israel | P. Home, UK | M. Mosseri, Israel | R. Taylor, UK |
| J. Davidson, USA | B. Itzhak, Israel | M. Nauck, Germany | M. Theodorakis, Greece |
| P.P. De Feo, Italy | H. Yki-Jarvinen, Finland | D. Neely, UK | I. Tkac, Slovakia |
| R.A. DeFronzo, USA | G. Jermendy, Hungary | P. Nilsson, Sweden | C. Tsigos, Greece |
| S. Del Prato, Italy | A. Karasik, Israel | P. Pozzilli, Italy | L. Van Gaal, Belgium |
| D. de Zeeuw, The Netherlands | N. Katsilambros, Greece | G. Parati, Italy | S. Vinker, Israel |
| D. Dicker, Israel | E.S. Kilpatrick, UK | M. Ravid, Israel | J. Vora, UK |
| P. Djordjevic, Serbia | Y. Kleinman, Israel | I. Raz, Israel | R. Weiss, Israel |
| M. Puig Domingo, Spain | F.K. Knop, Denmark | Y. Reznik, France | J. Wilding, UK |
| M. Donath, Switzerland | M. Laakso, Finland | L.M. Ruilope, Spain | R. Zimlichman, Israel |
| N. Finer, UK | N. Lalic, Serbia | S. Sadikot, India | |

PRELIMINARY SCIENTIFIC PROGRAM

THURSDAY, NOVEMBER 8, 2012

13:00-18:00 Novo Nordisk Satellite Symposium

19:00-20:00 **OPENING SESSION**
BREAKTHROUGHS IN DIABETES IN 2012

20:00-21:00 Welcome Reception

FRIDAY, NOVEMBER 9, 2012

HALL A

08:30-10:00 **PLENARY SESSION 1**
DIABETES AND CANCER

Chairs: **S. Del Prato, Italy; I. Raz, Israel**

Pathogenesis of cancers in diabetes and obesity

D. Leroith, USA

Insulin therapy and cancer

P. Home, UK

Oral agents and cancer (Metformin, Sulfonylureas, Thiazolidinediones)

R.A. DeFronzo, USA

Newer therapies and cancer (incretin and SGLT2)

M. Nauck, Germany

DISCUSSION: Do we need malignancy outcome studies?

10:00-10:30 Coffee Break

10:30-12:00 **SESSION 2**
CONTROVERSIES IN
DIABETES TREATMENT

Chair: **P. Djordjevic, Serbia**

How to start pharmacologic treatment?
Patho-physiological driven approach vs.
Guideline approach

Patho-physiological driven approach:

R.A. DeFronzo, USA

Guideline approach: **I. Raz, Israel**

How do we continue treatment in secondary failure?

Incretin vs. Insulin treatment

Incretin: **B. Gallwitz, USA**

Insulin: **R.G. Bretzel, Germany**

12:00-13:30 Lunch Break

13:30-15:30 **SESSION 3**
DIABETES, OBESITY AND
HYPERTENSION

Chair: **A. Lejnieks, Latvia**

Should we be targeting subclinical organ damage?

Yes: **E. Grossman, Israel**

No: **G. Mancia, Italy**

Should our targets for control be different in the elderly?

Obesity

C. Tsigos, Greece

Blood pressure control

G. Grassi, Italy

Lipid control

R. Bitzur, Israel

Blood glucose control

Y. Kleinman, Israel

15:30-16:00 Coffee Break

16:00-17:30 **SESSION 4**
DIABETES AND RELATED
DISORDERS

Sleep disorders

S. Sadikot, India

Pancreatitis

G. Marchesini, Italy

Alzheimer's disease

T. Cukierman-Yaffee, Israel

PRELIMINARY SCIENTIFIC PROGRAM

FRIDAY, NOVEMBER 9, 2012

HALL B

10:30-12:00 **SESSION 5** **NEWS IN HYPERTENSION**

Individualization of the management of hypertension

G. Mancia, Italy

Blood pressure (BP) variability or average BP is the main determinant of future cardiovascular (CV) outcomes

Pro-variability of BP: **G. Parati, Italy**

Pro-average BP: **L. Ruilope, Spain**

Diagnosis of hypertension should be by ambulatory monitoring

Pro: **E. Grossman, Israel**

Con: **P. Nilsson, Sweden**

12:00-13:30 *Lunch Break*

13:30-15:30 **SESSION 6** **OBESITY AND WEIGHT LOSS**

Chair: **D. Micic, Serbia**

Is obesity a brain disease?

Yes: **N. Stern, Israel**

No: **N. Finer, UK**

CV risk factors: The obesity paradox - Does it exist?

Against: **E. Standl, Germany**

In favor: **V. Hainer, Czech Republic**

Physical exercise is a core element for every patient

Yes: **P.P. De Feo, Italy**

No: **P. Schwarz, Denmark**

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 7** **BIARIATRIC SURGERY**

Chair: **L. Sjostrom, Sweden**

Mechanism of metabolic advantage after bariatric surgery

It's all food restrictions: **R. Taylor, UK**

It's all gastro-intestinal factors:

F.K. Knop, Denmark

Surgery during adolescence can be justified?

Yes: **R. Weiss, Israel**

No: **J.C. Holm, Denmark**

HALL C

10:30-12:00 **SESSION 8** **UNMET NEEDS IN OBESITY**

Obesity treatments: The state of the art

L. Van Gaal, Belgium

Bariatric surgery in the prevention of T2DM:

Long term experiences from the SOS study

L. Sjostrom, Sweden

From bariatric surgery to bariatric pill

G. Lieberman, Israel

Combining surgery and pharmacologic treatment

D. Dicker, Israel

12:30-13:30 *Lunch Break*

13:30-15:30 **SESSION 9** **THE KIDNEY AS A NEW THERAPEUTIC PARTNER**

Chair: **G. Schernthaner, Austria**

Hyperglycaemia, hypertension, obesity, and the kidney in people with T2DM

L. Van Gaal, Belgium

The kidney as a new therapeutic partner

J. Wilding, UK

Clinical potential of SGLT-2 inhibition

J. Seufert, Denmark

How this new approach may help tackle clinical inertia

M. Puig Domingo, Spain

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 10** **ONGOING DISCUSSIONS IN DIABETES AND METABOLIC SYNDROME**

Chair: **J. Skrha, Czech Republic**

Postprandial hyperglycaemic variability: Should we care?

Yes: **A. Ceriello, Spain**

No: **E.S. Kilpatrick, UK**

NAFLD/NASH - Is it an independent predictor of CV disease?

E. Bonora, Italy

18:00-20:30 **BMS/AZ Satellite Symposium**

PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, NOVEMBER 10, 2012

HALL A

08:30-10:00 **SESSION 11**
TYPE 2 DIABETES MELLITUS

Chair: **A. Ametov, Russia**

Should we begin by replacing insulin deficiency or reducing insulin insensitivity?

Early insulin replacement therapy:

A. Karasik, Israel

Early use of insulin sensitizers: TBA

Early insulinization to prevent diabetes progression

I. Raz, Israel

10:00-10:30 *Coffee Break*

10:30-12:00 **SESSION 12**
NEWS ON THE INCRETINS

Chair: **B. Itzhak, Israel**

New insights on the mechanisms of action of DPP-4 inhibitors

M. Nauck, Germany

A review of the cardiac and endothelial effects of incretin therapies

F. Giorgino, Italy

The pancreatic islet incretin system

M. Donath, Switzerland

12:00-13:30 *Lunch Break*

13:30-15:30 **SESSION 13**
INSULIN PUMP FOR T2DM

Chair: **F. Bonnici, South Africa**

Insulin pump for T2DM:

The use of CSII in T2DM

Y. Reznik, France

The misuse of CSII in T2DM

O. Cohen, Israel

Insulin analogues

A. Garber, USA

Intensification of insulin therapy in primary care, which is preferable - Basal Bolus vs. Premix

Premix

Basal Bolus: H. Yki-Jarvinen, Finland

Premix: O. Mosenzon, Israel

Discussion on current indications and future trends

15:30-16:00 *Coffee Break*

HALL A [continued]

16:00-17:30 **SESSION 14**
**CLINICAL DEVELOPMENT
OF GLUCOSE-LOWERING
MEDICATIONS: GLOBAL AND
REGIONAL**

Chair: **B. Hirshberg, Israel**

What type of data will we get from these large outcome studies?

C. Bailey, UK

Potential implications for clinical practice

S. Del Prato, Italy

A cardiologist in the endocrine world

TBA

Industry perspective

B. Hirshberg, Israel

HALL B

08:30-10:00 **SESSION 15**
**NEW TREATMENT
STRATEGIES**

Chair: **M. Shestakova, Russia**

How low blood glucose control?

Very low: P. Pozzilli, Italy

Not too low: E. Bonora, Italy

Individualization therapy- fashion or fact?

Fashion: C.J. Tack, The Netherlands

Fact: J. Davidson, USA

10:00-10:30 *Coffee Break*

10:30-12:00 **SESSION 16**
**THE UNSOLVED PROBLEM OF
HYPOGLYCAEMIA**

Chair: **G. Jermendy, Hungary**

Hypoglycaemia is of similar importance for every patient

Yes: S. Heller, UK

No: M. Theodorakis, Greece

Hypoglycaemia is of cardiovascular importance

Yes: N. Lalic, Serbia

No: I. Tkáč, Slovakia

12:00-13:30 *Lunch Break*

PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, NOVEMBER 10, 2012

HALL B [continued]

13:30-15:30 **SESSION 17**
HYPERTENSION

Should we treat proteinuria with more than one RAAS inhibitor?

Pro: R. Zimlichman, Israel

Con: D. de Zeeuw, The Netherlands

Should albuminuria be a target of treatment in hypertension?

H. Haller, Denmark

Reno-protection vs. cardio-protection: A clinical dilemma

M. Ravid, Israel

New opportunities for kidney protection in diabetes

A. Solini, Italy

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 18**
**LIFESTYLE THERAPIES FOR
DIABETES**

Prevention of diabetes: From research to practice

W. Cefalu, USA

Combination of GLP1 and insulin as 1st line therapy

J. Vora, UK

HALL C

08:30-10:00 **SESSION 19**
**TYPE 2 DIABETES MELLITUS
PART 2**

Impaired insulin secretion in T2DM

It's all beta cell mass: J. Meier, Germany

It's all beta cell function: R. Bonadonna, Italy

Genetic screening for the risk of diabetes- Valuable or worthless?

Valuable: M. Laakso, Finland

Worthless: V. Lyssenko, Sweden

10:00-10:30 *Coffee Break*

HALL C [continued]

10:30-12:00 **SESSION 20**
**LEARNING FROM THE
LITERATURE**

Chair: *N. Katsilambros, Greece*

Meta-analysis in diabetes: Both a salvation and a danger

P. Home, UK

Is glucose control important for prevention of cardiovascular disease in diabetes?

Yes: P. Pozzilli, Italy

No: E. Mannucci, Italy

12:00-13:30 *Lunch Break*

13:30-15:30 **SESSION 21**
**THE PLACE OF PPAR GAMA
THERAPY IN T2DM**

Chair: *R.A. DeFronzo, USA*

Molecular mechanism of action of TZDs: What does the future hold?

G. Scherthaner, Austria

In vivo actions of PPARs: Glycemic control, insulin sensitivity, insulin secretion

R.A. DeFronzo, USA

TZDs: Cardiovascular benefits far outweigh the risks

G. Scherthaner, Austria

15:30-16:00 *Coffee Break*

16:00-17:30 **SESSION 22**
**FUTURE THERAPY FOR
DIABETES**

GPR40 and TAK875

Clinical: C. Barrant, USA

Basic science: TBA

11-beta hydroxysteroid dehydrogenase: a therapeutic target for diabetes management?

A. Scheen, Belgium

PRELIMINARY SCIENTIFIC PROGRAM

SUNDAY, NOVEMBER 11, 2012

HALL A

08:30-10:00 **SESSION 23**
**DEBATES IN LIPID
MANAGEMENT**

Intolerance to statin drugs
Mechanisms of intolerance: **R. Bitzur, Israel**
How to manage the problem: **D. Neely, UK**

Residual CV risk in diabetes
We have reached the limit: **M. Mosseri, Israel**
There is still potential: **N. Marx, Germany**

10:00-10:30 *Coffee Break*

10:30-12:00 **SESSION 24**
**FUTURE THERAPEUTIC
APPROACHES**

ORIGIN trial-
The results/ A critical comment:
S. Del Prato, Italy

Translating the ORIGIN results into clinical
practice
M. Hanefeld, Germany

Future GLP-1R- Do they differ?
A. Garber, USA



GENERAL INFORMATION

VENUE

Palau De Congressos De Catalunya
Av. Diagonal, 661-671
Barcelona 08028, Spain
Tel: +34 (93) 364 4400
Fax: +34 (93) 364 4401
Website: www.pcongresos.com

LANGUAGE

The official language of the Congress is English.

REGISTRATION

	Early Registration until August 15, 2012	Late Registration from August 16, 2012	From November 1, 2012 & On Site
Participants - Physicians and Scientists	€540	€590	€650
Residents*	€380	€430	€470
Nurses and Students	€190	€240	€250

* Refers to non-tenured junior scientists. Registration form must be accompanied by documentation of residency or a letter from the head of department confirming their status. The letter should be on the department letterhead and addressed to the Registration Department of the Congress.

ABSTRACT SUBMISSION DEADLINE:

AUGUST 15, 2012

SPONSORS



Bristol-Myers Squibb

Working Together in Diabetes

AstraZeneca



Boehringer
Ingelheim



Medtronic

SANOFI DIABETES



comtecMED
MEDICAL CONGRESSES

www.codhy.com
codhy@codhy.com

Headquarters and Administration:

53 Rothschild Boulevard
PO Box 68
Tel Aviv 61000, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177
Email: info@comtecmed.com

Comtec Spain:

Bailén, 95-97
pral. 1. a - 08009
Barcelona, Spain
Tel: +34-93-2081145
Fax: +34-93-4579291
Email: spain@comtecmed.com

Comtec China:

175 Xiang Yang Road South
Shanghai 200031
China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com